PURIBLOOD MEDICAL CO., LTD.
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
PuriBlood Leukocyte Reduction Filter
Leukoreduction before transfusion is proved to benefit in reducing the adverse reaction and pathogen transmission in blood transfusion since 1985.
With our patented technology, the filter can precisely capture WBCs and yields a better result on the desired blood components.
Leukoreduction before transfusion is proved to benefit in reducing the adverse reaction and pathogen transmission in blood transfusion since 1985.
With our patented technology, the filter can precisely capture WBCs and yields a better result on the desired blood components.
Founded Year
2016
Unified Business No.
42770331
Status
Active
Number of Employees
0
Total Paid-in
Capital
142,300,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Emerging Stock Exchange(2021)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PuriBlood developed a unique technology for blood cell separation that is supported by a world-class research center the R and D center for membrane technology. PuriBlood is committed to improving the blood filtration process with the innovative technology of zwitterionic-bias surface coating technology. Filter housing transparent housingfacilitates monitoring priming and blood flow.
